Reducing the radiation therapy dose prescription for elective treatment areas in human papillomavirus-associated oropharyngeal carcinoma being treated with primary chemoradiotherapy at Memorial Sloan Kettering Cancer Center Journal Article

  

Authors:	Tsai, C. J.; McBride, S. M.; Riaz, N.; Lee, N. Y.
Article Title:	Reducing the radiation therapy dose prescription for elective treatment areas in human papillomavirus-associated oropharyngeal carcinoma being treated with primary chemoradiotherapy at Memorial Sloan Kettering Cancer Center
Abstract:	Data on the biology and radiosensitivity of human papillomavirus–related cancers have led many expert radiation oncologists to decrease the radiation dose to target areas in selected situations. At Memorial Sloan Kettering Cancer Center, we have altered our radiation guidelines to allow substantial dose reduction to elective treatment regions and to omit radiation completely in other regions that have historically been included in the elective treatment volume. Here we summarize our current dose prescriptions and briefly explain the rationale behind these choices, which we anticipate will change when additional data mature. These recommendations are based on the American Joint Committee on Cancer seventh edition TNM Staging System and applicable only to patients who receive concurrent platinum-based chemotherapy and in whom both p16 immunohistochemistry and human papillomavirus RNA in situ hybridization tests are positive. © 2018 American Society for Radiation Oncology
Journal Title:	Practical Radiation Oncology
Volume:	9
Issue:	2
ISSN:	1879-8519
Publisher:	Elsevier Inc.
Date Published:	2019-03-01
Start Page:	98
End Page:	101
Language:	English
DOI:	10.1016/j.prro.2018.10.015
PROVIDER:	scopus
PUBMED:	30445229
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85058457307&doi=10.1016%2fj.prro.2018.10.015&partnerID=40&md5=7a0b0af6c8357c0da999d5687ec6229e
Notes:	Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/142811